Pancreatic neuroendocrine tumor (pNET) is a rare cancer that affects the pancreas. For high-grade tumors, traditional chemotherapy drugs like cisplatin and etoposide are often used. Lurbinectedin, a new drug, has shown some success in lung cancer treatment and is being studied for pNET. In this study, patients will be treated with lurbinectedin to see how effective it is for high-grade pNET. To join, you must have a confirmed diagnosis of pNET and have tried other treatments without success. You should also have a certain level of white blood cells (ANC) and platelets, which are parts of your blood that help fight infections and stop bleeding. You cannot join if you are currently being treated for another cancer or are pregnant.

• This study involves trying a new drug, lurbinectedin, which is still being researched.
• You need to have tried other treatments that did not work before joining.
• You must not be pregnant or currently treated for another cancer.